As a leading full service CRO, PSI provides the services required to support global clinical trials, offering in-depth therapeutic experience across Phase I-IV clinical programs. We provide you with the expertise that is needed to conduct your clinical trial, whether it is a Phase I study, proof-of-concept or rescuing a pivotal study where enrollment is behind schedule; our goal is to complete your study on time!
For hematology studies, where competition for patients and complexity of design are leading characteristics, we apply our years of experience and relationships with investigators to manage and support their efforts to meet enrollment goals.
PSI has successfully performed Phase II/III studies in the following hematology indications:
- Chronic lymphocytic leukemia
- Idiopathic Thrombocytopenic Purpura
- Non-Hodgkin's Lymphoma
|
- Acute myeloid leukemia
- Multiple myeloma
- Thrombocytopenia
- Hemophilia A
|
- Secondary AML
- Hodgkin's Lymphoma
- Hemophilia B
|
PSI employs physicians as full-time monitors and project managers, most of whom are board certified specialists, including hematologists and oncologists. This gives us the ability to quickly and easily scale our services for hematology clinical trials of any size of complexity.
Please contact PSI to learn more about our hematology therapeutic expertise that can help you achieve on-time enrollment, meeting your study goals.
Case Study Examples: Hematology Indications Clinical Trial
